Drug Type Small molecule drug |
Synonyms MDM2 INHIBITOR AMG-232, AMG 232, AMG-232 + [3] |
Target |
Action inhibitors |
Mechanism MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC28H35Cl2NO5S |
InChIKeyDRLCSJFKKILATL-YWCVFVGNSA-N |
CAS Registry1352066-68-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Endometrial Cancer | Phase 3 | United States | 17 Jul 2023 | |
Recurrent Endometrial Cancer | Phase 3 | Austria | 17 Jul 2023 | |
Recurrent Endometrial Cancer | Phase 3 | Canada | 17 Jul 2023 | |
Recurrent Endometrial Cancer | Phase 3 | Denmark | 17 Jul 2023 | |
Recurrent Endometrial Cancer | Phase 3 | Estonia | 17 Jul 2023 | |
Recurrent Endometrial Cancer | Phase 3 | Finland | 17 Jul 2023 | |
Recurrent Endometrial Cancer | Phase 3 | Georgia | 17 Jul 2023 | |
Recurrent Endometrial Cancer | Phase 3 | Hungary | 17 Jul 2023 | |
Recurrent Endometrial Cancer | Phase 3 | Israel | 17 Jul 2023 | |
Recurrent Endometrial Cancer | Phase 3 | Italy | 17 Jul 2023 |
Phase 1 | Recurrent Glioblastoma TP53野生型 | 21 | Navtemadlin 120mg/240mg | cvculzcrfb(kqnwcsednx) = ervukhlbig kizmqfnnjq (ovmudgyehi ) | Positive | 27 Feb 2025 | |
Not Applicable | - | Navtemadlin 240 mg once-daily | edzqaoujro(zidfupwbxu) = wyljaihiur dldbdrcctt (nrktlhoogb ) View more | - | 09 Dec 2024 | ||
Best Available Therapy (BAT) | edzqaoujro(zidfupwbxu) = nqeqquypfe dldbdrcctt (nrktlhoogb ) View more | ||||||
Phase 3 | 113 | Nvtm 120 mg QD | rubtsxxfbc(goaoaylhew) = ovbkunylwj pmvpevfqyy (yczdbcudwm ) View more | - | 08 Jun 2023 | ||
Phase 1/2 | 32 | xedryotnxc(ozudlvkvcx) = aiohdjsbeo yspgqwzouk (gsmwckbrrj ) View more | - | 08 Jun 2023 | |||
Phase 1/2 | - | lmqjrdwtqx(riwqswxbnk) = pjwewladoj ntdlmksixr (ybrpdqqbov ) View more | Positive | 31 May 2023 | |||
NCT03787602 (ASCO2022) Manual | Phase 1/2 | Merkel Cell Carcinoma TP53 Wild-type | 29 | (7D on/ 14D off) | ltyqgkaavt(kvsdinoxgm) = vkyrpvczgz psqposbbyr (elcgvakwxf ) View more | Positive | 02 Jun 2022 |
(5D on/ 23D off) | ltyqgkaavt(kvsdinoxgm) = gidqiyednz psqposbbyr (elcgvakwxf ) View more | ||||||
Phase 1 | Soft Tissue Sarcoma Neoadjuvant | - | zkoayraveo(zkxkdnnzqc) = 120 mg 5x/week svgqlotkos (lziqqnuiic ) | Positive | 02 Jun 2022 | ||
NCT02110355 (Pubmed) Manual | Phase 1 | Metastatic melanoma TP53-wild type | 31 | nwbtqgbohm(pwcaibypou) = hetyjuswfa spvxsqlulf (dqownvtufz ) View more | Positive | 30 May 2022 | |
nwbtqgbohm(pwcaibypou) = ejzdigessc spvxsqlulf (dqownvtufz ) View more | |||||||
Phase 1 | 107 | ebqwxvxfky(aqweefsvbr) = diarrhea, nausea, vomiting, fatigue, decreased appetite, and anemia sssjugtlna (mrbcgegdui ) View more | Positive | 01 Jun 2020 | |||
Phase 1 | 36 | qiybgbkbya(hiwhaskckn) = Common treatment-related AEs (any grade) included nausea (58%), diarrhea (56%), vomiting (33%), and decreased appetite (25%). ixnormvczw (scgdtrthdb ) | Positive | 09 Jul 2019 | |||